129 related articles for article (PubMed ID: 2084074)
1. Phase II study of lonidamine in patients with metastatic breast cancer. An Eastern Cooperative Oncology Group study.
Robins HI; Neuberg DS; Benson AB; Pandya KJ; Tormey DC
Invest New Drugs; 1990 Nov; 8(4):397-9. PubMed ID: 2084074
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of lonidamine in patients with metastatic breast cancer: a National Cancer Institute of Canada Clinical Trials Group Study.
Band PR; Maroun J; Pritchard K; Stewart D; Coppin CM; Wilson K; Eisenhauer EA
Cancer Treat Rep; 1986 Nov; 70(11):1305-10. PubMed ID: 3768873
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of lonidamine in metastatic breast cancer.
Pronzato P; Amoroso D; Bertelli G; Conte PF; Cusimano MP; Ciottoli GB; Gulisano M; Lionetto R; Rosso R
Br J Cancer; 1989 Feb; 59(2):251-3. PubMed ID: 2930690
[TBL] [Abstract][Full Text] [Related]
4. Fluorouracil, doxorubicin, and cyclophosphamide versus fluorouracil, doxorubicin, and cyclophosphamide plus lonidamine for the treatment of advanced breast cancer: a multicentric randomized clinical study.
Calabresi F; Di Lauro L; Marolla P; Curcio CG; Paoletti G; Calabró A; Giannarelli D; Ballatore P; Foggi CM; Di Palma M
Semin Oncol; 1991 Apr; 18(2 Suppl 4):66-72. PubMed ID: 2031201
[TBL] [Abstract][Full Text] [Related]
5. Modulating effect of lonidamine on response to doxorubicin in metastatic breast cancer patients: results from a multicenter prospective randomized trial.
Amadori D; Frassineti GL; De Matteis A; Mustacchi G; Santoro A; Cariello S; Ferrari M; Nascimben O; Nanni O; Lombardi A; Scarpi E; Zoli W
Breast Cancer Res Treat; 1998 Jun; 49(3):209-17. PubMed ID: 9776504
[TBL] [Abstract][Full Text] [Related]
6. Lonidamine versus high-dose tamoxifen in progressive, advanced renal cell carcinoma: results of an ongoing randomized phase II study.
Stahl M; Schmoll E; Becker H; Schlichter A; Hoffmann L; Wagner H; Possinger K; Müller W; Köllermann M; Weidenhammer W
Semin Oncol; 1991 Apr; 18(2 Suppl 4):33-7. PubMed ID: 2031196
[TBL] [Abstract][Full Text] [Related]
7. The role of lonidamine in the treatment of breast cancer patients.
Rosso R; Gardin G; Pronzato P; Camoriano A; Merlini L; Naso C; Rosso M; Barone C; Nascimben O; Ianniello G
Ann N Y Acad Sci; 1993 Nov; 698():349-56. PubMed ID: 8279774
[No Abstract] [Full Text] [Related]
8. Lonidamine in metastatic breast cancer.
Rosso R; Amoroso D; Gardin G; Miglietta L; Guido T; Pace M; Repetto L; Pronzato P
Semin Oncol; 1991 Apr; 18(2 Suppl 4):62-5. PubMed ID: 2031200
[TBL] [Abstract][Full Text] [Related]
9. Other options in the treatment of advanced breast cancer.
Cobleigh MA
Semin Oncol; 2011 Jun; 38 Suppl 2():S11-6. PubMed ID: 21600380
[TBL] [Abstract][Full Text] [Related]
10. Cisplatin and epirubicin plus oral lonidamine as first-line treatment for metastatic breast cancer: a phase II study of the Southern Italy Oncology Group (GOIM).
Gebbia V; Borsellino N; Testa A; Latteri MA; Milia V; Valdesi M; Giotta F; Gebbia N; Colucci G
Anticancer Drugs; 1997 Nov; 8(10):943-8. PubMed ID: 9436637
[TBL] [Abstract][Full Text] [Related]
11. Lonidamine in advanced colorectal cancer: a phase II study of the Italian Oncology Group for Clinical Research (GOIRC).
Passalacqua R; Bisagni G; Bertusi M; Donati D; Buzzi F; Di Costanzo F; Basurto C; Gori S
Tumori; 1989 Jun; 75(3):277-9. PubMed ID: 2672481
[TBL] [Abstract][Full Text] [Related]
12. Lonidamine in high-risk breast cancer patients.
Possinger K; Wagner H; Kovacs S; Flath B; Classen S; Wilmanns W
Semin Oncol; 1991 Apr; 18(2 Suppl 4):58-61. PubMed ID: 2031199
[TBL] [Abstract][Full Text] [Related]
13. Phase I toxicologic study of Lonidamine in cancer patients.
Band PR; Deschamps M; Besner JG; Leclaire R; Gervais P; De Sanctis A
Oncology; 1984; 41 Suppl 1():56-9. PubMed ID: 6717896
[TBL] [Abstract][Full Text] [Related]
14. A phase II clinical and pharmacokinetic study of Lonidamine in patients with advanced breast cancer.
Mansi JL; de Graeff A; Newell DR; Glaholm J; Button D; Leach MO; Payne G; Smith IE
Br J Cancer; 1991 Sep; 64(3):593-7. PubMed ID: 1911204
[TBL] [Abstract][Full Text] [Related]
15. Emerging drugs in metastatic breast cancer: an update.
Arslan C; Altundag K; Dizdar O
Expert Opin Emerg Drugs; 2011 Dec; 16(4):647-67. PubMed ID: 22122529
[TBL] [Abstract][Full Text] [Related]
16. Phase III trial with and without lonidamine in non-small cell lung cancer.
Gatzemeier U; Cavalli F; Häussinger K; Kaukel E; Koschel G; Martinelli G; Neuhauss R; von Pawel J
Semin Oncol; 1991 Apr; 18(2 Suppl 4):42-8. PubMed ID: 1851577
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of Lonidamine in cancer patients.
Band PR; Deschamps M; Besner JG; Leclaire R; Gervais P; De Sanctis A
Oncology; 1984; 41 Suppl 1():66-8. PubMed ID: 6717898
[TBL] [Abstract][Full Text] [Related]
18. Early observations on the administration of Lonidamine in cancer patients.
Barduagni A; Barduagni M; Di Lauro L; Nardi M; Gallo Curcio C; Tonachella R; Ciottoli GB; Delle Chiaie S
Oncology; 1984; 41 Suppl 1():78-81. PubMed ID: 6717900
[TBL] [Abstract][Full Text] [Related]
19. Lonidamine: efficacy and safety in clinical trials for the treatment of solid tumors.
Di Cosimo S; Ferretti G; Papaldo P; Carlini P; Fabi A; Cognetti F
Drugs Today (Barc); 2003 Mar; 39(3):157-74. PubMed ID: 12730701
[TBL] [Abstract][Full Text] [Related]
20. A phase II evaluation of combination chemotherapy plus aminoglutethimide in women with metastatic or recurrent breast carcinoma. An Eastern Cooperative Oncology Group Pilot Study.
Grem JL; Falkson G; Love RR; Tormey DC
Am J Clin Oncol; 1988 Oct; 11(5):528-34. PubMed ID: 3177253
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
